세계 HIV 진단 시장 : 제품별, 검사 유형별, 최종 사용자별, 지역별 분석(-2030년)

According to Stratistics MRC, the Global HIV Diagnosis Market is accounted for $1059.6 million in 2023 and is expected to reach $1757.9 million by 2030 growing at a CAGR of 7.4% during the forecast period. HIV diagnosis refers to the process of identifying the presence of the human immunodeficiency virus (HIV) in an individual's body. It is typically accomplished through various laboratory tests that detect specific markers of the virus, such as HIV antibodies or viral genetic material in blood, saliva, or other bodily fluids. The accurate diagnosis is essential for determining an individual's HIV status, which is crucial for initiating treatment, managing the disease, and preventing its spread.

According to the World Health Organization (WHO), in 2016, around 36 million people were diagnosed with HIV globally, of which 2.1 million were reported to be cases of new HIV infections.

Market Dynamics:

Driver:

Rising demand for HIV diagnosis

Since the human immunodeficiency virus (HIV), which causes acquired immunodeficiency syndrome, may be detected by HIV diagnostics, by which there is an increasing need for these services. Moreover, testing serum, saliva, or urine samples allows for the diagnosis of HIV and as these methods assist in detecting antibodies, antigens, and RNA, it is projected that sales of HIV diagnostic processes will rise. Additionally, as people become more knowledgeable about HIV, the confidentiality of the test, and appropriate counselling, the demand for HIV diagnostics is also rising. Hence, the HIV diagnostics market is anticipated to expand quickly as a result of these factors.

Restraint:

High expenses

HIV diagnostic tests can be expensive, particularly for more sophisticated and precise testing procedures, depending on the context and type of test. Additionally, costs associated with testing can be an obstacle, especially in environments with few resources or for people without access to adequate healthcare. Consequently, this considerably disrupts the market's expansion.

Opportunity:

Government schemes and programs

Worldwide, governments are stepping up their efforts to tackle the HIV/AIDS pandemic by putting in place comprehensive plans that prioritize prevention, testing, and treatment. Additionally, these programs seek to increase the prevalence of routine HIV testing, particularly among high-risk populations, and to open up access to cutting-edge diagnostic tools. Furthermore, governments also encourage collaborations among pharmaceutical firms, non-governmental organizations (NGOs), and healthcare organizations to increase the accessibility and cost of HIV diagnostic equipment, which in turn drives market expansion as they cooperate to mitigate the burden of HIV worldwide

Threat:

Lack of knowledge and false-positive results

A lot of people, especially those who live in high-risk areas, can be unaware of the value of early diagnosis and have limited knowledge about HIV testing. Low testing rates and delayed diagnoses might be caused by a lack of education and awareness actions, hindering adequate management and prevention measures. Furthermore, false-positive results can result in too much worry and stress, while false-negative results can delay diagnosis and increase the risk of virus transmission. Thus, these factors gradually hamper the size of the market.

COVID-19 Impact

The global lockdown caused by the corona virus (COVID-19) pandemic has had an effect on the financial health of companies in all industries. Additionally, global supply chains and manufacturing operations have been affected as a result of government-enforced lockdowns, mobility restrictions, and other COVID-19 safety measures. Therefore, during the epidemic, the need for HIV diagnostic tests is anticipated to decline.

The instruments segment is expected to be the largest during the forecast period

The instruments segment is estimated to hold the largest share, due to utilizing specialized medical tools and technology, HIV infection is detected and tracked. Additionally, these technologies enable medical personnel to precisely identify HIV antibodies or viral genetic material in patient samples. Examples of these devices include diagnostic tools including PCR machines, ELISA analyzers, and quick test readers. Moreover, these cutting-edge tools are essential for early detection, disease monitoring, and research, enabling quick and accurate HIV testing. They also assist healthcare professionals, labs, and clinics in delivering efficient diagnostic solutions, which helps to further the continuing efforts to restrict the spread of HIV. Therefore, these factors significantly drive the market's size.

The CD4 Tests segment is expected to have the highest CAGR during the forecast period

The CD4 Tests segment is anticipated to have highest CAGR during the forecast period. CD4 tests are essential for controlling HIV/AIDS since they show the disease's course and measure the patient's immune system's health. Additionally, these tests assist medical professionals in deciding on a course of treatment and assessing the efficacy of antiretroviral medication. Moreover, for directing patient care and managing diseases, accurate and prompt CD4 testing is essential. Thus, it contributes to better treatment outcomes and overall quality of life for people with HIV by playing a vital role in the market for HIV diagnosis.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period owing to increasing awareness-raising campaigns in nations like India, China, and Japan have increased the number of HIV diagnoses. Moreover, because of shifting socioeconomic and demographic factors, there are more HIV diagnoses in these nations. Additionally, rising healthcare institution and awareness program investments are driving market expansion in the Asia Pacific region.

Region with highest CAGR:

Europe is expected to witness highest CAGR over the projection period, owing to significant progress in boosting early detection, creating national testing policies, and increasing access to HIV testing services. Additionally, the area aims to reduce the stigma and discrimination related to HIV, which encourages people to be tested. Furthermore, governments, healthcare institutions, and NGOs working together have increased testing rates and accelerated diagnosis which thus significantly propels the market expansion in Europe region.

Key players in the market:

Some of the key players in the HIV Diagnosis Market include: Abbott Laboratories, Roche Diagnostics, Merck KGaA, Siemens Healthineers, Thermo-Fisher Scientific Inc., Beckman Coulter, Inc., Hologic Inc., Becton, Dickinson & Company , Bio-Rad Laboratories, Alere Inc., OraSure Technologies, Inc., Zyomyx Incorporation, Chembio Diagnostic Systems, Inc., Janssen Pharmaceutica NV and Bristol -Myers Squibb.

Key Developments:

In August 2023, Abbott Laboratories has collaborated with Redcliffe Labs to introduce Clinical Decision Support (CDS) also known as AlinIQ, powered by various proprietary technologies including Big Data Engines and Artificial Intelligence (AI). This development aims to revolutionise healthcare, offering solutions to enhance patient care and convenience.

In Jan 2022, Bristol-Myers Squibb and Century Therapeutics enter into a strategic collaboration to develop iPSC-derived Allogeneic Cell Therapies. The collaboration with Century Therapeutics is an important part of their investment strategy in next-generation cell therapies for hematologic and solid tumors.

Products Covered:

• Software & Services
• Instruments
• Consumables

Test Types Covered:

• Antibody Tests
• Viral Load Tests
• Tests for Early Infant Diagnosis
• CD4 Tests
• Tests for Viral Identification

End Users Covered:

• Hospitals & Clinics
• Diagnostic Laboratories
• Home Settings
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global HIV Diagnosis Market, By Product

• 5.1 Introduction
• 5.2 Software & Services
• 5.3 Instruments
• 5.4 Consumables
  • 5.4.1 Assays and Kits & Reagents
  • 5.4.2 Other Consumables

6 Global HIV Diagnosis Market, By Test Type

• 6.1 Introduction
• 6.2 Antibody Tests
  • 6.2.1 HIV-1 Screening Tests
    • 6.2.1.1 Elisa
    • 6.2.1.2 Home Access Dried Blood Spots
    • 6.2.1.3 Rapid Tests
  • 6.2.2 HIV-1 Antibody Confirmatory Tests
    • 6.2.2.1 Western Blot Tests
    • 6.2.2.2 Line Immunoassays
    • 6.2.2.3 Indirect Immunofluorescence Assays (IFA)
    • 6.2.2.4 Radio-Immunoprecipitation Assays
  • 6.2.3 HIV-2 & Group O Diagnostic Tests
• 6.3 Viral Load Tests
• 6.4 Tests for Early Infant Diagnosis
• 6.5 CD4 Tests
• 6.6 Tests for Viral Identification

7 Global HIV Diagnosis Market, By End User

• 7.1 Introduction
• 7.2 Hospitals & Clinics
• 7.3 Diagnostic Laboratories
• 7.4 Home Settings
• 7.5 Other End Users

8 Global HIV Diagnosis Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Abbott Laboratories
• 10.2 Roche Diagnostics
• 10.3 Merck KGaA
• 10.4 Siemens Healthineers
• 10.5 Thermo-Fisher Scientific Inc.
• 10.6 Beckman Coulter, Inc.
• 10.7 Hologic Inc.
• 10.8 Becton, Dickinson & Company
• 10.9 Bio-Rad Laboratories
• 10.10 Alere Inc.
• 10.11 OraSure Technologies, Inc.
• 10.12 Zyomyx Incorporation
• 10.13 Chembio Diagnostic Systems, Inc.
• 10.14 Janssen Pharmaceutica NV
• 10.15 Bristol -Myers Squibb